Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 134.5% in July

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 234,700 shares, agrowthof134.5% from the June 30th total of 100,100 shares. Based on an average trading volume of 719,200 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 719,200 shares, the short-interest ratio is presently 0.3 days.

Analyst Ratings Changes

Several brokerages recently commented on BAYRY. Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 11th. The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. Wall Street Zen lowered Bayer Aktiengesellschaft from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. Finally, Kepler Capital Markets raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy".

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $7.90 on Tuesday. The company has a market capitalization of $31.04 billion, a PE ratio of -8.58 and a beta of 0.91. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.79 and a current ratio of 1.25. The business's fifty day moving average is $7.79 and its 200 day moving average is $6.69. Bayer Aktiengesellschaft has a fifty-two week low of $4.79 and a fifty-two week high of $8.65.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. The company had revenue of $15.27 billion for the quarter, compared to the consensus estimate of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 13.94% and a negative net margin of 7.26%. Sell-side analysts predict that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.